Hide metadata

dc.date.accessioned2018-08-12T09:51:20Z
dc.date.available2018-08-12T09:51:20Z
dc.date.created2017-10-30T13:52:33Z
dc.date.issued2017
dc.identifier.citationNestvold, Janne M. Wang, Mengyu Camilio, Ketil Andre Zinöcker, Severin Tjelle, Torunn Elisabeth Lindberg, Alf Haug, Bengt Erik Kvalheim, Gunnar Sveinbjørnsson, Baldur Rekdal, Øystein . Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. Oncoimmunology. 2017, 6(8:e1338236), 1-13
dc.identifier.urihttp://hdl.handle.net/10852/62863
dc.description.abstractLTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as demonstrated by the regression of distal non-treated lesions. Significant infiltration of CD8+ T cells was observed in both treated and non-treated lesions, as shown by immunohistochemical and flow cytometric analysis. LTX-315 rapidly killed the cells in vitro with a lytic mode of action followed by the subsequent release of Danger-Associated Molecular Pattern (DAMP) molecules such as HMGB1, ATP and Cytochrome c. Together, our data demonstrate that LTX-315 represents a new approach to cancer immunotherapy, which has the potential as a novel immunotherapeutic agent.en_US
dc.languageEN
dc.publisherLandes Bioscience
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleOncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma modelen_US
dc.typeJournal articleen_US
dc.creator.authorNestvold, Janne M.
dc.creator.authorWang, Mengyu
dc.creator.authorCamilio, Ketil Andre
dc.creator.authorZinöcker, Severin
dc.creator.authorTjelle, Torunn Elisabeth
dc.creator.authorLindberg, Alf
dc.creator.authorHaug, Bengt Erik
dc.creator.authorKvalheim, Gunnar
dc.creator.authorSveinbjørnsson, Baldur
dc.creator.authorRekdal, Øystein
cristin.unitcode185,51,12,30
cristin.unitnameSeksjon for anatomi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1508953
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Oncoimmunology&rft.volume=6&rft.spage=1&rft.date=2017
dc.identifier.jtitleOncoimmunology
dc.identifier.volume6
dc.identifier.issue8:e1338236
dc.identifier.startpage1
dc.identifier.endpage13
dc.identifier.doihttp://dx.doi.org/10.1080/2162402X.2017.1338236
dc.identifier.urnURN:NBN:no-65432
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn2162-402X
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/62863/2/oncoimmunol.2017.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International